4D Molecular Therapeutics Inc (FDMT) - Net Assets
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has net assets worth $505.66 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($566.71 Million) and total liabilities ($61.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore 4D Molecular Therapeutics Inc cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $505.66 Million |
| % of Total Assets | 89.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | 58.46% |
| 10-Year Change | N/A |
| Growth Volatility | 31.58 |
4D Molecular Therapeutics Inc - Net Assets Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore FDMT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Annual Net Assets for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual net assets of 4D Molecular Therapeutics Inc from 2017 to 2025. For live valuation and market cap data, see FDMT market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $505.66 Million | -0.97% |
| 2024-12-31 | $510.61 Million | +65.87% |
| 2023-12-31 | $307.83 Million | +33.07% |
| 2022-12-31 | $231.34 Million | -27.50% |
| 2021-12-31 | $319.11 Million | +24.46% |
| 2020-12-31 | $256.39 Million | +451.36% |
| 2019-12-31 | $-72.97 Million | -164.51% |
| 2018-12-31 | $-27.59 Million | -40.82% |
| 2017-12-31 | $-19.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 4D Molecular Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 69582900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $727.00K | 0.14% |
| Other Components | $1.22 Billion | 241.51% |
| Total Equity | $505.66 Million | 100.00% |
4D Molecular Therapeutics Inc Competitors by Market Cap
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chang Lan Electric Technology Co Ltd
SHE:002879
|
$451.84 Million |
|
Ideal United Bintang Bhd
KLSE:9687
|
$451.92 Million |
|
Tianjin Jinbin Development
SHE:000897
|
$452.02 Million |
|
Solus Advanced Materials Co Ltd
KO:336370
|
$452.03 Million |
|
NAPATECH A/S NAM. DK 025
F:NAT
|
$451.66 Million |
|
Thaitheparos Public Company Limited
BK:SAUCE
|
$451.64 Million |
|
Chongqing Mas Sci&Tech
SHE:300275
|
$451.61 Million |
|
Zhangjiagang Zhonghuan Hailu High-End Equipment Co. Ltd.
SHE:301040
|
$451.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 4D Molecular Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 510,606,000 to 505,664,000, a change of -4,942,000 (-1.0%).
- Net loss of 140,109,000 reduced equity.
- Share repurchases of 7,500,000 reduced equity.
- New share issuances of 110,723,000 increased equity.
- Other comprehensive income increased equity by 498,000.
- Other factors increased equity by 31,446,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-140.11 Million | -27.71% |
| Share Repurchases | $7.50 Million | -1.48% |
| Share Issuances | $110.72 Million | +21.9% |
| Other Comprehensive Income | $498.00K | +0.1% |
| Other Changes | $31.45 Million | +6.22% |
| Total Change | $- | -0.97% |
Book Value vs Market Value Analysis
This analysis compares 4D Molecular Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.32 | $8.85 | x |
| 2018-12-31 | $-2.20 | $8.85 | x |
| 2019-12-31 | $-2.75 | $8.85 | x |
| 2020-12-31 | $9.61 | $8.85 | x |
| 2021-12-31 | $11.51 | $8.85 | x |
| 2022-12-31 | $7.15 | $8.85 | x |
| 2023-12-31 | $7.87 | $8.85 | x |
| 2024-12-31 | $9.47 | $8.85 | x |
| 2025-12-31 | $8.73 | $8.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 4D Molecular Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -164.43%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.12x
- Recent ROE (-27.71%) is below the historical average (-19.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -193.83% | 0.21x | 0.00x | $-9.26 Million |
| 2018 | 0.00% | -67.59% | 0.15x | 0.00x | $-6.79 Million |
| 2019 | 0.00% | -705.78% | 0.12x | 0.00x | $-42.01 Million |
| 2020 | -22.11% | -416.49% | 0.05x | 1.12x | $-82.33 Million |
| 2021 | -21.40% | -378.63% | 0.05x | 1.11x | $-100.21 Million |
| 2022 | -43.69% | -3230.30% | 0.01x | 1.13x | $-124.21 Million |
| 2023 | -32.76% | -486.59% | 0.06x | 1.10x | $-131.62 Million |
| 2024 | -31.51% | -434778.38% | 0.00x | 1.10x | $-211.93 Million |
| 2025 | -27.71% | -164.43% | 0.15x | 1.12x | $-190.68 Million |
Industry Comparison
This section compares 4D Molecular Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 4D Molecular Therapeutics Inc (FDMT) | $505.66 Million | 0.00% | 0.12x | $451.81 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more